JP2006504749A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006504749A5 JP2006504749A5 JP2004544226A JP2004544226A JP2006504749A5 JP 2006504749 A5 JP2006504749 A5 JP 2006504749A5 JP 2004544226 A JP2004544226 A JP 2004544226A JP 2004544226 A JP2004544226 A JP 2004544226A JP 2006504749 A5 JP2006504749 A5 JP 2006504749A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- hydrate
- acceptable salt
- bisphosphonate
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 25
- 150000003839 salts Chemical group 0.000 claims description 25
- 229940122361 Bisphosphonate Drugs 0.000 claims description 23
- 150000004663 bisphosphonates Chemical class 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims description 7
- 208000004434 Calcinosis Diseases 0.000 claims description 7
- 210000004204 blood vessel Anatomy 0.000 claims description 7
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 7
- 206010072810 Vascular wall hypertrophy Diseases 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 230000002308 calcification Effects 0.000 claims description 6
- 238000013508 migration Methods 0.000 claims description 6
- -1 salt form bisphosphonate Chemical class 0.000 claims description 6
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 6
- 108091008605 VEGF receptors Proteins 0.000 claims description 5
- 230000003143 atherosclerotic effect Effects 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- MXYOPVWZZKEAGX-UHFFFAOYSA-N 1-phosphonoethylphosphonic acid Chemical compound OP(=O)(O)C(C)P(O)(O)=O MXYOPVWZZKEAGX-UHFFFAOYSA-N 0.000 claims description 4
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 4
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- 230000001028 anti-proliverative effect Effects 0.000 claims description 3
- 230000006907 apoptotic process Effects 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 230000008021 deposition Effects 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 3
- 229960004276 zoledronic acid Drugs 0.000 claims description 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 12
- 102000001301 EGF receptor Human genes 0.000 claims 7
- 108060006698 EGF receptor Proteins 0.000 claims 7
- 230000007423 decrease Effects 0.000 claims 5
- 108091008606 PDGF receptors Proteins 0.000 claims 4
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims 4
- 102000036530 EDG receptors Human genes 0.000 claims 3
- 108091007263 EDG receptors Proteins 0.000 claims 3
- 108091000080 Phosphotransferase Proteins 0.000 claims 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- 210000002997 osteoclast Anatomy 0.000 claims 3
- 102000020233 phosphotransferase Human genes 0.000 claims 3
- 239000000018 receptor agonist Substances 0.000 claims 3
- 229940044601 receptor agonist Drugs 0.000 claims 3
- 230000000087 stabilizing effect Effects 0.000 claims 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims 2
- 241001149724 Cololabis adocetus Species 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 102000029749 Microtubule Human genes 0.000 claims 2
- 108091022875 Microtubule Proteins 0.000 claims 2
- 108010055723 PDGF receptor tyrosine kinase Proteins 0.000 claims 2
- 229940046731 calcineurin inhibitors Drugs 0.000 claims 2
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 210000004688 microtubule Anatomy 0.000 claims 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- PMXAPNNYCFBALB-UHFFFAOYSA-N (1-hydroxy-1-phosphono-3-pyrrolidin-1-ylpropyl)phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCN1CCCC1 PMXAPNNYCFBALB-UHFFFAOYSA-N 0.000 claims 1
- RDFHOSXBGDLRQF-UHFFFAOYSA-N (2-anilino-1-phosphono-2-sulfanylideneethyl)phosphonic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)C(=S)NC1=CC=CC=C1 RDFHOSXBGDLRQF-UHFFFAOYSA-N 0.000 claims 1
- NEAHTABRXFKZGG-UHFFFAOYSA-N 2-pyridin-4-yl-3h-imidazo[4,5-c]pyridine Chemical compound C1=NC=CC(C=2NC3=CN=CC=C3N=2)=C1 NEAHTABRXFKZGG-UHFFFAOYSA-N 0.000 claims 1
- PYSGFFTXMUWEOT-UHFFFAOYSA-N 3-(dimethylamino)propan-1-ol Chemical compound CN(C)CCCO PYSGFFTXMUWEOT-UHFFFAOYSA-N 0.000 claims 1
- 229940122739 Calcineurin inhibitor Drugs 0.000 claims 1
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 claims 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 claims 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims 1
- PQBAWAQIRZIWIV-UHFFFAOYSA-N N-methylpyridinium Chemical class C[N+]1=CC=CC=C1 PQBAWAQIRZIWIV-UHFFFAOYSA-N 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims 1
- QWCNOXMFNSYEKF-UHFFFAOYSA-N [1-hydroxy-3-[methyl(2-phenylsulfanylethyl)amino]-1-phosphonopropyl]phosphonic acid Chemical compound OP(=O)(O)C(O)(P(O)(O)=O)CCN(C)CCSC1=CC=CC=C1 QWCNOXMFNSYEKF-UHFFFAOYSA-N 0.000 claims 1
- NPLHDPAQRZJWHX-UHFFFAOYSA-N [5,5-bis(diethoxyphosphoryl)-1,4-dihydropyrazol-3-yl]-phenylmethanone Chemical compound N1C(P(=O)(OCC)OCC)(P(=O)(OCC)OCC)CC(C(=O)C=2C=CC=CC=2)=N1 NPLHDPAQRZJWHX-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229960004343 alendronic acid Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 229960002286 clodronic acid Drugs 0.000 claims 1
- 230000000368 destabilizing effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 229960005236 ibandronic acid Drugs 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000012106 negative regulation of microtubule depolymerization Effects 0.000 claims 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 claims 1
- 229960003978 pamidronic acid Drugs 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 229960000759 risedronic acid Drugs 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 208000005475 Vascular calcification Diseases 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- 208000037411 Aortic calcification Diseases 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- FBSQLNMIJFINOJ-UHFFFAOYSA-N (2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)CN1C=CN=C1 FBSQLNMIJFINOJ-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000014882 Carotid artery disease Diseases 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- IKOGYRLPQONMFM-UHFFFAOYSA-N [1-amino-2-(1-benzylimidazol-4-yl)-1-phosphonoethyl]phosphonic acid Chemical compound C1=NC(CC(N)(P(O)(O)=O)P(O)(O)=O)=CN1CC1=CC=CC=C1 IKOGYRLPQONMFM-UHFFFAOYSA-N 0.000 description 1
- VGCUFGXAHRPSNF-UHFFFAOYSA-N [1-amino-2-(1-methylimidazol-4-yl)-1-phosphonoethyl]phosphonic acid Chemical compound CN1C=NC(CC(N)(P(O)(O)=O)P(O)(O)=O)=C1 VGCUFGXAHRPSNF-UHFFFAOYSA-N 0.000 description 1
- WXNDCAILNRCPMQ-UHFFFAOYSA-N [1-hydroxy-1-phosphono-2-(1,2,4-triazol-4-yl)ethyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=NN=C1 WXNDCAILNRCPMQ-UHFFFAOYSA-N 0.000 description 1
- KXZAQOYIXOBXMR-UHFFFAOYSA-N [1-hydroxy-2-(1-methylimidazol-2-yl)-1-phosphonoethyl]phosphonic acid Chemical compound CN1C=CN=C1CC(O)(P(O)(O)=O)P(O)(O)=O KXZAQOYIXOBXMR-UHFFFAOYSA-N 0.000 description 1
- VSLQUGGYXRLUSL-UHFFFAOYSA-N [1-hydroxy-2-(1-methylimidazol-4-yl)-1-phosphonoethyl]phosphonic acid Chemical compound CN1C=NC(CC(O)(P(O)(O)=O)P(O)(O)=O)=C1 VSLQUGGYXRLUSL-UHFFFAOYSA-N 0.000 description 1
- JGERUCQQMGBXSJ-UHFFFAOYSA-N [1-phosphono-2-(1,3-thiazol-2-yl)ethyl]phosphonic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)CC1=NC=CS1 JGERUCQQMGBXSJ-UHFFFAOYSA-N 0.000 description 1
- VVTWQGRTVMQHIS-UHFFFAOYSA-N [2-(1-benzylimidazol-2-yl)-1-hydroxy-1-phosphonoethyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=NC=CN1CC1=CC=CC=C1 VVTWQGRTVMQHIS-UHFFFAOYSA-N 0.000 description 1
- IASQSZOLHNXZJJ-UHFFFAOYSA-N [2-(1-benzylimidazol-2-yl)-1-phosphonoethyl]phosphonic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)CC1=NC=CN1CC1=CC=CC=C1 IASQSZOLHNXZJJ-UHFFFAOYSA-N 0.000 description 1
- BDTDCXHWLYHYOO-UHFFFAOYSA-N [2-(1-methylimidazol-2-yl)-1-phosphonoethyl]phosphonic acid Chemical compound CN1C=CN=C1CC(P(O)(O)=O)P(O)(O)=O BDTDCXHWLYHYOO-UHFFFAOYSA-N 0.000 description 1
- XFDRFWQRYYEEEI-UHFFFAOYSA-N [2-(1h-imidazol-2-yl)-1-phosphonoethyl]phosphonic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)CC1=NC=CN1 XFDRFWQRYYEEEI-UHFFFAOYSA-N 0.000 description 1
- KWNLTXMGFAGRNR-UHFFFAOYSA-N [2-(4,5-dimethylimidazol-1-yl)-1-hydroxy-1-phosphonoethyl]phosphonic acid Chemical compound CC=1N=CN(CC(O)(P(O)(O)=O)P(O)(O)=O)C=1C KWNLTXMGFAGRNR-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 208000037876 carotid Atherosclerosis Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 210000004513 dentition Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- CEYUIFJWVHOCPP-UHFFFAOYSA-L disodium;(3-amino-1-hydroxy-1-phosphonatopropyl)phosphonic acid Chemical compound [Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O CEYUIFJWVHOCPP-UHFFFAOYSA-L 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000036346 tooth eruption Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41855402P | 2002-10-15 | 2002-10-15 | |
| US42862102P | 2002-11-22 | 2002-11-22 | |
| PCT/EP2003/011379 WO2004035060A1 (en) | 2002-10-15 | 2003-10-14 | Bisphosphonates for the treatment of antheroscleorosis and devices comprising them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006504749A JP2006504749A (ja) | 2006-02-09 |
| JP2006504749A5 true JP2006504749A5 (enExample) | 2006-11-30 |
Family
ID=32110165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004544226A Pending JP2006504749A (ja) | 2002-10-15 | 2003-10-14 | アテローム性動脈硬化症の処置のためのビスホスホネートおよびそれらを含むデバイス |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20060166937A1 (enExample) |
| EP (1) | EP1553957A1 (enExample) |
| JP (1) | JP2006504749A (enExample) |
| AU (1) | AU2003268939A1 (enExample) |
| BR (1) | BR0315383A (enExample) |
| CA (1) | CA2502284A1 (enExample) |
| HK (1) | HK1080370A1 (enExample) |
| TW (1) | TW200410700A (enExample) |
| WO (1) | WO2004035060A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050033417A1 (en) * | 2003-07-31 | 2005-02-10 | John Borges | Coating for controlled release of a therapeutic agent |
| US8071574B2 (en) * | 2005-02-22 | 2011-12-06 | John Dennis Bobyn | Implant improving local bone formation |
| EP2473172B1 (en) | 2009-09-01 | 2015-04-08 | Duke University | Bisphosphonate compositions and methods for treating heart failure |
| CN104010647A (zh) * | 2011-11-16 | 2014-08-27 | 杜克大学 | 用于治疗和/或减轻心功能障碍的双膦酸盐组合物及方法 |
| TWI730039B (zh) * | 2016-01-29 | 2021-06-11 | 日商富士藥品股份有限公司 | 新穎雙膦酸化合物 |
| FR3068233A1 (fr) * | 2017-07-03 | 2019-01-04 | Omnium De Revalorisation Industrielle Odri | Dispositif medical intra-arteriel et applications |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5157027A (en) * | 1991-05-13 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Bisphosphonate squalene synthetase inhibitors and method |
| IL125336A0 (en) * | 1998-07-14 | 1999-03-12 | Yissum Res Dev Co | Compositions for inhibition and treatment of restinosis |
| EP1267888A4 (en) * | 2000-01-04 | 2005-12-28 | Univ California | USE OF LOW DOSE BISPHOSPHONATES TO INHIBIT CARDIAC AND ARTERIAL CALCIFICATION |
| JP2001253827A (ja) * | 2000-02-15 | 2001-09-18 | Pfizer Prod Inc | 骨粗鬆症を治療するための組成物および方法 |
| US20030064965A1 (en) * | 2001-10-02 | 2003-04-03 | Jacob Richter | Method of delivering drugs to a tissue using drug-coated medical devices |
| US7090865B2 (en) * | 2001-11-29 | 2006-08-15 | National Jewish Medical And Research Center | Composition and method for treating autoimmune hemolytic anemia |
-
2003
- 2003-10-14 TW TW092128543A patent/TW200410700A/zh unknown
- 2003-10-14 WO PCT/EP2003/011379 patent/WO2004035060A1/en not_active Ceased
- 2003-10-14 CA CA002502284A patent/CA2502284A1/en not_active Abandoned
- 2003-10-14 BR BR0315383-5A patent/BR0315383A/pt not_active IP Right Cessation
- 2003-10-14 US US10/531,677 patent/US20060166937A1/en not_active Abandoned
- 2003-10-14 AU AU2003268939A patent/AU2003268939A1/en not_active Abandoned
- 2003-10-14 HK HK06100249.3A patent/HK1080370A1/zh unknown
- 2003-10-14 EP EP03750714A patent/EP1553957A1/en not_active Withdrawn
- 2003-10-14 JP JP2004544226A patent/JP2006504749A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002257802B2 (en) | Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer | |
| JP4722375B2 (ja) | ビホスホネートの投与法 | |
| CZ20031467A3 (cs) | Léčivo obsahující bisfosfonát pro ošetřování bolesti | |
| JP2004528340A5 (enExample) | ||
| AU2002257802A1 (en) | Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer | |
| MX2009001630A (es) | Composiciones en nanoparticulas. | |
| US20130138221A1 (en) | Methods and compositions for improving implant osseointegration | |
| JP2003500352A5 (enExample) | ||
| JP2006504749A5 (enExample) | ||
| CN1327844C (zh) | 包含双膦酸类化合物和hmg－coa还原酶抑制剂的组合疗法 | |
| JP2006500401A5 (enExample) | ||
| JP2006504749A (ja) | アテローム性動脈硬化症の処置のためのビスホスホネートおよびそれらを含むデバイス | |
| CN1705486A (zh) | 用于治疗动脉粥样硬化的双膦酸类化合物和包含它们的装置 | |
| HK1080735A (en) | Bisphosphonates for the treatment of antheroscleorosis and devices comprising them | |
| US8748410B2 (en) | Methods of treating aneurysm | |
| HK1080711B (en) | Use of bisphosphonates for the munufacture of a medicament for the treatment of bone metastasis associated with prostate cancer |